Vertigo (HP:0002321)
An abnormal sensation of spinning while the body is actually stationary.
Synonyms: Dizzy spell, Dizziness
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Calcium signaling pathway | 0.000004013 | 0.0001445 | 55.80 | 693.40 |
| 2 | Adrenergic signaling in cardiomyocytes | 0.00004774 | 0.0008593 | 57.85 | 575.61 |
| 3 | Cardiac muscle contraction | 0.0008229 | 0.009193 | 58.54 | 415.82 |
| 4 | Circadian entrainment | 0.001021 | 0.009193 | 52.36 | 360.55 |
| 5 | Citrate cycle (TCA cycle) | 0.01490 | 0.06706 | 76.48 | 321.69 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | membrane depolarization during action potential (GO:0086010) | 6.190e-13 | 1.752e-10 | 950.90 | 26730.60 |
| 2 | membrane depolarization during AV node cell action potential (GO:0086045) | 0.000002248 | 0.00003535 | 1665.58 | 21661.60 |
| 3 | membrane depolarization during SA node cell action potential (GO:0086046) | 0.000002248 | 0.00003535 | 1665.58 | 21661.60 |
| 4 | SA node cell to atrial cardiac muscle cell signaling (GO:0086018) | 0.000002248 | 0.00003535 | 1665.58 | 21661.60 |
| 5 | cardiac muscle cell action potential involved in contraction (GO:0086002) | 1.597e-12 | 1.785e-10 | 767.85 | 20856.82 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | voltage-gated sodium channel activity (GO:0005248) | 2.480e-13 | 8.184e-12 | 1174.88 | 34101.37 |
| 2 | voltage-gated sodium channel activity involved in cardiac muscle cell action potential (GO:0086006) | 0.000002248 | 0.00002473 | 1665.58 | 21661.60 |
| 3 | sodium channel activity (GO:0005272) | 4.712e-12 | 7.774e-11 | 604.76 | 15772.67 |
| 4 | voltage-gated calcium channel activity involved in cardiac muscle cell action potential (GO:0086007) | 0.002498 | 0.01374 | 555.17 | 3326.77 |
| 5 | nitric-oxide synthase binding (GO:0050998) | 0.003495 | 0.01647 | 370.07 | 2093.27 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | voltage-gated sodium channel complex (GO:0001518) | 5.833e-14 | 1.867e-12 | 1664.83 | 50731.79 |
| 2 | sodium channel complex (GO:0034706) | 5.000e-13 | 8.001e-12 | 998.50 | 28281.59 |
| 3 | junctional sarcoplasmic reticulum membrane (GO:0014701) | 0.000008085 | 0.00003696 | 713.68 | 8368.26 |
| 4 | calcium channel complex (GO:0034704) | 0.000001263 | 0.00001347 | 203.55 | 2764.61 |
| 5 | sarcoplasmic reticulum membrane (GO:0033017) | 0.00008446 | 0.0003003 | 191.96 | 1800.45 |
Hub genes predicted as biomarkers & predicted FDA approved drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| SCN5A | INDECAINIDE, BENZONATATE, FOSPHENYTOIN, MORICIZINE, HEXYLCAINE, PROCAINAMIDE, MEXILETINE, DISOPYRAMIDE |
| SCN2A | – |
| SCN1A | ETHOSUXIMIDE |
| CACNA1G | ETHOSUXIMIDE, ZONISAMIDE, TRIMETHADIONE, METHSUXIMIDE, PARAMETHADIONE, FLUNARIZINE, PHENSUXIMIDE |
| RYR2 | PROCAINE |
| SCN1B | ZONISAMIDE |
| CASQ2 | – |
| NF1 | TRAMETINIB, BINIMETINIB, COBIMETINIB, DABRAFENIB, VEMURAFENIB |
| RET | CABOZANTINIB, VANDETANIB |
| SDHC | – |
